Benzinga | May 24, 2021 11:44AM EDT

Raymond James Downgrades NGM Biopharmaceuticals to Outperform, Lowers Price Target to $22

Raymond James analyst Steven Seedhouse downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Strong Buy to Outperform and lowers the price target from $52 to $22.